22 December 2023
Backed by billionaire tech moguls Peter Thiel and Sam Altman, Johnson’s gene therapy treatment aims to boost muscle mass and bone density while reducing body fat, with hopes of extending his lifespan to 200 years.
Bryan Johnson, the 46-year-old tech mogul known for his extreme anti-aging regimen, has recently undergone a radical gene therapy treatment in his quest for immortality. The therapy, offered by startup company Minicircle Inc. and backed by billionaire tech moguls Peter Thiel and Sam Altman, claims to enhance muscle mass and bone density while reducing body fat. Johnson, who spends $2 million a year on anti-aging treatments, hopes that this gene therapy will help him reach his goal of living to the age of 200. However, the treatment has faced skepticism from scientists who question its efficacy and safety.
1: The Promise of Gene Therapy
Johnson believes that gene therapies have the potential to extend human lifespan beyond what traditional methods like diet, exercise, and sleep can achieve. By undergoing gene therapy, he hopes to unlock the secrets of longevity and push the boundaries of human life expectancy. While his current regimen includes various anti-aging practices, he sees gene therapy as the missing piece of the puzzle.
2: The Minicircle Inc. Treatment
Minicircle Inc., the company behind Johnson’s gene therapy treatment, operates primarily out of Roatán, a tropical island off the coast of Honduras. The choice of location is due to the island’s lax regulations, which are necessary for a treatment that has yet to be approved by the US Food and Drug Administration. The therapy aims to increase the body’s production of follistatin, a protein that triggers muscle production, leading to improved muscle mass and overall physical performance.
3: Skepticism and Concerns
Despite the claims made by Minicircle Inc., the scientific community remains skeptical of the gene therapy treatment. Critics argue that there is a lack of evidence to support the efficacy of the therapy and raise concerns about potential side effects, such as cancer or liver failure. Physician and neuroscientist Christin Glorioso has been particularly vocal in his criticism, stating that these therapies do not make scientific sense and could be dangerous.
4: Promising Results and Early Trials
Minicircle Inc. asserts that their gene therapy treatment has shown promising results in early trials. According to the company, the therapy introduces new genetic instructions into human cells, leading to improved tissue composition, increased lifespan in mice, and various health benefits in humans. In a trial involving 44 participants between the ages of 23 and 89, the therapy reportedly reduced genetic age by an average of 11 years, while also improving muscle mass, bone density, and overall well-being.
5: Bryan Johnson’s Influence and Impact
Bryan Johnson’s decision to undergo the Minicircle Inc. gene therapy treatment has garnered significant attention. With his high-profile status and documented anti-aging regimen, Johnson has become a cult figure among those interested in longevity and immortality. The attention he brings to Minicircle Inc. may attract a larger clientele and further the development of gene therapies.
Conclusion:
Bryan Johnson’s pursuit of immortality through gene therapy highlights the growing interest and investment in anti-aging technologies. While the Minicircle Inc. treatment has shown promising early results, skepticism remains within the scientific community. As research and development in gene therapy continue, it is crucial to balance the potential benefits with the need for rigorous testing and safety precautions. Johnson’s journey serves as a reminder of the human desire for longevity and the ongoing quest to unlock the secrets of aging.
